The Patent Finder

Idera Pharmaceuticals, Inc.

Also on record
Records under this name other than the patents Idera Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.

Back to Idera Pharmaceuticals, Inc.

PatentTitleStatus Expires Confidence
US 8,853,177Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto
Lapsed on the fee record
Ended Oct 7, 2026 · High confidence
Lapsed on the fee recordEnded Oct 7, 2026High confidence
US 8,853,375Toll Like Receptor Modulators
Lapsed on the fee record
Ended Oct 7, 2026 · High confidence
Lapsed on the fee recordEnded Oct 7, 2026High confidence
US 10,066,230Immune Regulatory Oligonucleotide (IRO) Compounds to Modulate Toll-Like Receptor Based Immune Response
Lapsed on the fee record
Ended Sep 4, 2026 · Medium confidence
Lapsed on the fee recordEnded Sep 4, 2026Medium confidence
US 7,749,975Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
Term ended
Term ended Aug 27, 2026 · From the USPTO record
Term endedTerm ended Aug 27, 2026From the USPTO record
US 10,041,076Immune Regulatory Oligonucleotide (IRO) Compounds to Modulate Toll-Like Receptor Based Immune Response
Lapsed on the fee record
Ended Aug 7, 2026 · Medium confidence
Lapsed on the fee recordEnded Aug 7, 2026Medium confidence
US 8,759,310Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
Lapsed on the fee record
Ended Jun 24, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jun 24, 2026From the USPTO record
US 7,569,554Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
Term ended
Term ended May 6, 2026 · From the USPTO record
Term endedTerm ended May 6, 2026From the USPTO record
US 11,224,611Immune modulation with TLR9 agonists for cancer treatment
Lapsed on the fee record
Ended Jan 18, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jan 18, 2026From the USPTO record
US 9,828,601Compositions for inhibiting checkpoint gene expression and uses thereof
Lapsed on the fee record
Ended Nov 28, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 28, 2025From the USPTO record
US 8,946,175Stabilized Immunomodulatory Oligonucleotides
Term ended
Ended no later than Oct 10, 2025 · Low confidence
Term endedEnded no later than Oct 10, 2025Low confidence
10 of 153 patents shown.
Pro members see all 153.
Pro members: see all 153 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited